Insider · CIK 0001550967
Christopher Ryan Schadel
Files at ZSQR (Coeptis Therapeutics Holdings, Inc.). First filing Aug 20, 2026, latest Oct 2, 2026.
In brief
Christopher Ryan Schadel files SEC Form 4 as officer at ZSQR (Coeptis Therapeutics Holdings, Inc.). Since Aug 20, 2026, Christopher Ryan Schadel has reported 2 open-market buys worth $7,840 and 0 open-market sells worth $0, the latest filed on Oct 2, 2026.
A track record needs three past buys with six months of prices behind them; Christopher Ryan Schadel has 0, so none is measured yet.
The newest scored trade: bought $3,920 of ZSQR on Aug 18, 2026, filed Oct 2, 2026, scored 39 (weak). In the last 12 months: 2 buys worth $7,840 and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZSQR: Coeptis Therapeutics Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | ZSQRbuy Coeptis Therapeutics Holdings, Inc. | $3,920 1,000 shares | +41% | 0% from low-80% from high | |
| 41Moderate | ZSQRbuy Coeptis Therapeutics Holdings, Inc. | $3,920 1,000 shares | - | 0% from low-80% from high |
Transactions
Every row this insider has filed, 12 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | MOption exercise Common Stock | +2,467 | $0.00 | $0 | 2,467 | 11 d ago |
| Aug 18, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | POpen-market purchase Common Stock | +1,000 | $3.92 | $3,920 | 3,467 | 11 d ago |
| Sep 3, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | MOption exercise Common Stock | +702 | $0.00 | $0 | 4,169 | 11 d ago |
| Jul 27, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | MOption exercise Restricted Stock Unitsderivative | -2,467 | $0.00 | $0 | 10,207 | 11 d ago |
| Sep 3, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | MOption exercise Restricted Stock Unitsderivative | -702 | $0.00 | $0 | 9,505 | 11 d ago |
| Aug 18, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | POpen-market purchase Common Stock | +1,000 | $3.92 | $3,920 | 1,000 | Aug 20, 2026 |
| Jun 3, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Restricted Stock Unitsderivative | +2,806 | $0.00 | $0 | 12,674 | Aug 20, 2026 |
| Apr 27, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Aug 20, 2026 |
| Apr 27, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Restricted Stock Unitsderivative | +9,868 | $0.00 | $0 | 9,868 | Aug 20, 2026 |
| Jun 3, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Restricted Stock Unitsderivative | +2,806 | $0.00 | $0 | 12,674 | Jun 8, 2026 |
| Apr 27, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 30, 2026 |
| Apr 27, 2026 | ZSQR Coeptis Therapeutics Holdings, Inc. | AGrant or award Restricted Stock Unitsderivative | +9,868 | $0.00 | $0 | 9,868 | Apr 30, 2026 |
Questions about Christopher Ryan Schadel
Answered from the filings on this page, as of the latest one.
Is Christopher Ryan Schadel buying or selling?
In the last 12 months Christopher Ryan Schadel reported 2 open-market buys worth $7,840 and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $3,920 of ZSQR on Aug 18, 2026. Grants, option exercises and tax withholding are not counted.
How did Christopher Ryan Schadel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Ryan Schadel has 0.
Where does Christopher Ryan Schadel file Form 4?
Christopher Ryan Schadel has filed Form 4 at ZSQR (Coeptis Therapeutics Holdings, Inc.) as Chief Marketing Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.